Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.

Abstract:

:Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammopathies of undetermined significance (MGUS). Microvessel density increased in parallel with the labeling index (LI%)--an indicator of plasma cell proliferating activity that correlates with prognosis--and defined a risk of MM progression in much the same way as LI% itself. Consequently, bone marrow angiogenesis could be an indication for unfavourable prognosis in MGUS and MM. Angiogenesis has also been demonstrated in lymph nodes involved by B cell non Hodgkin's lymphoma (B-NHL) belonging to the Working Formulation intermediate-grade (diffuse subtypes), and high-grade categories, but not in the low-grade and intermediate-grade (follicular subtype) categories. It correlated with the B-NHL cell proliferating activity, since large increments in this activity have already been demonstrated in intermediate- and high-grade vs low-grade tumors. Active MM, intermediate-grade, diffuse subtypes, and high-grade B-NHLs correspond to the vascular phases of B cell lymphoproliferative diseases, and could thus be assimilated to locally invasive and metastatic solid tumors. Similarly to solid tumors during these stages of progression, tumor B cells are also capable of inducing angiogenesis, both directly and indirectly by activating the inflammation infiltrate--a possibility that was first demonstrated by means of B-NHL implants onto the chick embryo chorioallantoic membrane. Anti-angiogenic therapy can be envisaged as a possible future development.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Vacca A,Ribatti D,Roncali L,Dammacco F

doi

10.3109/10428199509054750

subject

Has Abstract

pub_date

1995-12-01 00:00:00

pages

27-38

issue

1-2

eissn

1042-8194

issn

1029-2403

journal_volume

20

pub_type

杂志文章,评审
  • Prognostic value of cytogenetic abnormalities in previously untreated patients with non-Hodgkin's lymphoma.

    abstract::In this study cytogenetic findings have been correlated with prognosis in 78 previously untreated patients with non-Hodgkin's lymphoma (NHL) presenting between 1983 and 1988. The median follow-up was 7 years (range 2-9 years). There was no significant difference in the duration of survival of 33 patients with only abn...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709039037

    authors: Juneja S,Matthews J,Lukeis R,Laidlaw C,Cooper I,Wolf M,Ironside P,Garson OM

    更新日期:1997-05-01 00:00:00

  • Increased circulating CD3+ T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma.

    abstract::Non-malignant host immune cells are the main substrate in classical Hodgkin lymphoma (HL) microenvironment. Reconstitution of lymphocyte populations following the high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (auto-HSCT) can support tumor growth in HL patients. We investigated re...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1581934

    authors: Batorov EV,Pronkina NV,Tikhonova MA,Kryuchkova IV,Sergeevicheva VV,Sizikova SA,Ushakova GY,Aristova TA,Batorova DS,Shishkova IV,Gilevich AV,Shevela EY,Ostanin AA,Chernykh ER

    更新日期:2019-10-01 00:00:00

  • Rapamycin enhances dimethyl sulfoxide-mediated growth arrest in human myelogenous leukemia cells.

    abstract::Rapamycin and its derivatives have been proposed in the treatment of leukemia based on their cytostatic effects, but their possible role in differentiation therapy is less explored. The aim of the present study was to investigate the possible beneficial effects of the combination of rapamycin and dimethyl sulfoxide (D...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.684351

    authors: Lalic H,Lukinovic-Skudar V,Banfic H,Visnjic D

    更新日期:2012-11-01 00:00:00

  • New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression.

    abstract::Multiple myeloma is a malignant condition that most commonly occurs in the seventh decade of life. Recent improvements in treatment may result in a more favourable outlook for recently diagnosed patients. Multiple myeloma is an incurable clonal B-cell malignancy, which is initially responsive to conventional chemother...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190802475311

    authors: Gertz MA

    更新日期:2008-12-01 00:00:00

  • Tocilizumab for steroid refractory acute graft-versus-host disease.

    abstract::Acute graft-versus-host-disease (aGVHD) is a frequent and often lethal complication of allogeneic hematopoietic stem cell transplant despite prophylaxis. Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody that has evidence of activity in patients with steroid refractory (SR) GVHD. We retrospectively rep...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1045896

    authors: Roddy JV,Haverkos BM,McBride A,Leininger KM,Jaglowski S,Penza S,Klisovic R,Blum W,Vasu S,Hofmeister CC,Benson DM,Andritsos LA,Devine SM,Efebera YA

    更新日期:2016-01-01 00:00:00

  • Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.

    abstract::Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1205741

    authors: Pozzi S,Gentile M,Sacchi S,Marcheselli R,Corso A,Cocito F,Musto P,Guarini A,Minoia C,Vincelli I,Ria R,Rivolti E,Mele G,Bari A,Mazzone C,Badiali S,Marcheselli L,Palumbo A,Morabito F

    更新日期:2017-03-01 00:00:00

  • Dipeptidyl peptidase IV: serum activity and expression on lymphocytes in different hematological malignancies.

    abstract::The aim of this research was to determine the serum dipeptidyl peptidase IV (DPPIV) activity as well as the percentages of CD26 + lymphocytes and CD26 + overall white blood cells in patients with hematological malignancies: non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), leukemia, plasmacytoma and multiple myeloma,...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.782611

    authors: Matić IZ,Đorđević M,Đorđić M,Grozdanić N,Damjanović A,Kolundžija B,Vidović A,Bila J,Ristić S,Mihaljević B,Tomin D,Milanović N,Ristić D,Purić M,Gavrilović D,Cordero OJ,Juranić ZD

    更新日期:2013-12-01 00:00:00

  • Historical aspects and milestones in the development of effective treatment for hairy cell leukemia.

    abstract::Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder, but is gratifying to treat for both physicians and patients. During the 50 years since its initial description as a clinical entity, hematologists have been fascinated by the bizarre appearance of the malignant cell with its hair-like projections...

    journal_title:Leukemia & lymphoma

    pub_type: 历史文章,杂志文章,评审

    doi:10.3109/10428190903219667

    authors: Tallman MS,Polliack A

    更新日期:2009-10-01 00:00:00

  • Clofarabine: past, present, and future.

    abstract::Clofarabine is a good generation purine nucleoside analogue designed to overcome the limitations and to incorporate the best qualities of both cladribine and fludarabine. Clofarabine is thought to work via three mechanisms: inhibition of ribonucleotide reductase; incorporation to DNA; and induction of apoptosis. Given...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190701545644

    authors: Kantarjian HM,Jeha S,Gandhi V,Wess M,Faderl S

    更新日期:2007-10-01 00:00:00

  • Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene.

    abstract::Donor T cells have a critical role in promoting engraftment after allogeneic bone marrow transplantation (BMT), but also cause graft versus host disease (GVHD). Ex vivo T cell depletion has been an effective strategy to reduce GVHD but has been associated with impaired alloengraftment and host immunity. Using an MHC-m...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000016041

    authors: Drobyski WR,Gendelman M

    更新日期:2002-10-01 00:00:00

  • Molecular pathogenesis of mucosal-associated lymphoid tissue (MALT) lymphoma.

    abstract::Extranodal marginal zone B-cell lymphomas of mucosal-associated lymphoid tissue (MALT)-type occur in a number of anatomic sites, but share overlapping morphological and immunophenotypic features. Helicobacter pylori infection has been identified as an etiological factor in gastric MALT lymphoma, but the cause of MALT ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190310001623793

    authors: Gascoyne RD

    更新日期:2003-01-01 00:00:00

  • The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.

    abstract::From July 1983 to January 1991 a total of 622 patients were randomized (585 eligible) to compare the effects of hydroxyurea, interferon alpha (IFN), and busulfan on the duration of chronic phase, and survival. Further goals included the determination of prognostic parameters. 598 CML patients were documented and 575 e...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428199309047880

    authors: Hehlmann R,Heimpel H,Kolb HJ,Heinze B,Hochhaus A,Griesshammer M,Pralle H,Queisser WP,Essers U,Falge C

    更新日期:1993-01-01 00:00:00

  • Evaluation of hemodynamic parameters among patients with myeloproliferative neoplasms and suspected pulmonary hypertension.

    abstract::Myeloproliferative neoplasms (MPNs) are associated with pulmonary hypertension (PH). We studied MPN patients who underwent right-heart-catheterization (RHC) to identify hemodynamic differences between MPN-subtypes. Per RHC, hemodynamics were classified as pre, post or combined pre and post-capillary PH. One-way analys...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1864351

    authors: Khan NA,Ahuja KA,Wang X,Chaisson NF

    更新日期:2021-01-25 00:00:00

  • Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.

    abstract::High-dose therapy (HDT) is now recommended for patients under 60 years of age with chemosensitive relapsed aggressive non-Hodgkin's lymphoma. However, approximately half of these patients will be cured by HDT. Prognostic factors are needed to predict which patients with chemosensitive lymphoma to second-line therapy c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500054350

    authors: Jabbour E,Peslin N,Arnaud P,Ferme C,Carde P,Vantelon JM,Bocaccio C,Bourhis JH,Koscielny S,Ribrag V

    更新日期:2005-06-01 00:00:00

  • Vaccine therapy in NHL: future promises and current limitations.

    abstract::Recent advances in genomics are revealing new molecular targets for vaccination strategies in cancer, and unraveling the immune pathways that must be activated. Initially, work focused on idiotypic antigen expressed by the clonal immunoglobulin (Ig) of B-cell tumors. This involved assembling the encoding V(H) and V(L)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190310001623711

    authors: Stevenson FK,King A,Ottensmeier CH

    更新日期:2003-01-01 00:00:00

  • SOX11 and HIG-2 are cross-regulated and affect growth in mantle cell lymphoma.

    abstract::The transcriptional factor SOX11 is a disease-defining antigen in mantle cell lymphoma (MCL) and absent in most non-malignant tissues. To explore the role of SOX11-related cell signaling, and potentially take benefit from these for targeted therapy, associated networks and proteins need to be defined. In this study, w...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1121257

    authors: Kuci V,Nordström L,Conrotto P,Ek S

    更新日期:2016-08-01 00:00:00

  • Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma.

    abstract::Gene array studies on follicular lymphoma (FL) have associated non-malignant tumor-infiltrating immune cells with patient survival. We examined the role of such cells detectable by immunohistochemistry in a tissue microarray, focusing on plasmacytoid dendritic cells (pDCs). These cells physiologically produce interfer...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.569619

    authors: Butsch R,Lukas Waelti S,Schaerer S,Braun J,Korol D,Probst-Hensch N,Moch H,Kurrer M

    更新日期:2011-07-01 00:00:00

  • Proposals for a Phenotypic Classification of B-Chronic Lymphocytic Leukemia, Relationship with Prognostic Factors.

    abstract::Immunophenotypic analysis was performed in 53 cases of B chronic lymphocytic leukemia using a large panel of monoclonal antibodies recognizing B, T, activation and myeloid antigens. Our results showed four patterns of reactivity: (a) several molecules were constantly expressed: CD19, CD20, CD24, CD37, HLA-DR, mu heavy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109103379

    authors: Legac E,Chastang C,Binet JL,Michel A,Debre P,Merle-Beral H

    更新日期:1991-01-01 00:00:00

  • ZAP-70 in B cell malignancies.

    abstract::ZAP-70 has emerged as a protein of potential prognostic importance in chronic lymphocytic leukemia (CLL) following gene expression profiling which compared the 2 well established prognostic sub-sets, those with unmutated and mutated IgVH genes. This protein tyrosine kinase (PTK), known to be of importance in T and NK ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/09638280500260079

    authors: Orchard J,Ibbotson R,Best G,Parker A,Oscier D

    更新日期:2005-12-01 00:00:00

  • The late adverse events of rituximab therapy--rare but there!

    abstract::Rituximab, an anti CD20 monoclonal antibody, has now become a cornerstone in the treatment of many CD20 positive hematological malignancies and a variety of autoimmune disorders. In contrast to the acute allergic and cytokine associated reactions, late adverse events of rituximab are indeed uncommon but at the same ti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190902934944

    authors: Ram R,Ben-Bassat I,Shpilberg O,Polliack A,Raanani P

    更新日期:2009-07-01 00:00:00

  • Bone marrow scintigraphy as a useful method for estimating the physiological status of bone marrow and spleen in polycythaemia vera.

    abstract::Bone marrow scintigraphy is a simple and noninvasive examination useful to define the status of the bone marrow and spleen in polycythaemia vera (P.V.). Despite the absence of specificity of Indium 111 labelled transferrin (In-Tf) for myelopoietic tissue, there is a close correlation between bone marrow In-Tf uptake a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609074367

    authors: Rain JD,Najean Y,Billotey C

    更新日期:1996-09-01 00:00:00

  • Double isochromosome 8q as single cytogenetic aberration in acute myelo-monocytic leukemia.

    abstract::We report a case of double isochromosome 8q as a single cytogenetic abnormality in a patient with acute myelo-monocytic leukemia. Similarly to rare cases with tetrasomy 8, the patient showed monocytic involvement and was refractory to cytotoxic chemotherapy. We conclude that this kind of cytogenetic aberration is prob...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509107909

    authors: Vicari L,Sebastio L,Cirigliano V,Pugliese MT,Ferrara F

    更新日期:1995-10-01 00:00:00

  • Impact of thymidylate synthase promoter and DNA repair gene polymorphisms on susceptibility to childhood acute lymphoblastic leukemia.

    abstract::The aim of this study was to evaluate the frequency of polymorphisms in the TYMS, XRCC1, and ERCC2 DNA repair genes in pediatric patients with acute lymphoblastic leukemia using polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism (RFLP) approaches. The study was conducted in 206 patients a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.559672

    authors: Canalle R,Silveira VS,Scrideli CA,Queiroz RG,Lopes LF,Tone LG

    更新日期:2011-06-01 00:00:00

  • Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.

    abstract::Low muscle mass (LMM) and low muscle density (LMD) are increasingly recognized as prognostic factors for survival in different malignancies. This study determined the association of LMM and LMD with survival in DLBCL (diffuse large B-cell lymphoma) patients. CT-based measurement of muscle was performed in 164 DLBCL pa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1737686

    authors: Rier HN,Kharagjitsing H,van Rosmalen J,van Vugt J,Westerweel PE,de Jongh E,Kock M,Levin MD

    更新日期:2020-07-01 00:00:00

  • STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas.

    abstract::Constitutively activated STAT3 is correlated with more advanced clinical stage and overall poor survival of diffuse large B-cell lymphoma (DLBCL). The aim of this study was to evaluate STAT3 and Ki67 tumor cell expression, inflammatory cell infiltration, microvascular density in DLBCL bioptic specimens. RNA-scope show...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1678154

    authors: Tamma R,Ingravallo G,Gaudio F,Annese T,Albano F,Ruggieri S,Dicataldo M,Maiorano E,Specchia G,Ribatti D

    更新日期:2020-03-01 00:00:00

  • Acute trilineage leukemia with monosomy of chromosome 7 following an acute promyelocytic leukemia.

    abstract::We describe an 8 year old boy who had received chemotherapy for an acute promyelocytic leukemia and developed a secondary leukemia 27 months after the diagnosis of this first malignancy. Blasts cells were positive for cytoplasmic markers CD22, CD3 and myeloperoxidase. Cell surface T and myeloid-associated markers were...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909050968

    authors: Felice MS,Rossi J,Gallego M,Zubizarreta PA,Cygler AM,Alfaro E,Sackmann-Muriel F

    更新日期:1999-07-01 00:00:00

  • Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients.

    abstract::The lung is a relatively rare site for mucosa-associated lymphoid tissue (MALT) lymphomas: we report the largest available single-center series of patients with this presentation. From August 1992 to October 2000, 12 patients with untreated primary low-grade MALT lymphoma of the lung were submitted either to chemother...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000067972

    authors: Zinzani PL,Tani M,Gabriele A,Poletti V,Stefoni V,Alinari L,Musuraca G,Bonifazi F,Pileri S,Tura S,Baccarani M

    更新日期:2003-05-01 00:00:00

  • Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis.

    abstract::Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patie...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500237450

    authors: Mazzotta S,Gozzetti A,Pirrotta MT,Bocchia M,Sammassimo S,Bucalossi A,Lauria F

    更新日期:2005-12-01 00:00:00

  • Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML.

    abstract::Consolidation chemotherapy in acute myeloid leukemia (AML) aims at eradicating residual leukemic cells and mostly comprises high-dose cytarabine with or without the addition of anthracyclines, including daunorubicin. Immunogenic cell death (ICD) may contribute to the efficacy of anthracyclines in solid cancer, but the...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1599110

    authors: Aurelius J,Möllgård L,Kiffin R,Ewald Sander F,Nilsson S,Thorén FB,Hellstrand K,Martner A

    更新日期:2019-11-01 00:00:00

  • Lymphoma survivors have an increased long-term risk of chronic kidney disease.

    abstract::With improving lymphoma survival, late effects of therapy have emerged. Here, we describe pattern of long-term chronic kidney disease (CKD) in lymphoma survivors. Demographics, comorbidities, lymphoma histology, treatment, and outcome were recorded. Glomerular filtration rate (GFR) was recorded at diagnosis, 1, 2, 5, ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1786555

    authors: Desai SH,Al-Shbool G,Desale S,Veis J,Malkovska V

    更新日期:2020-12-01 00:00:00